← Back to patent-cliff list
Imlunestrant Tosylate
Tier C — Watch / tradeImlunestrant Tosylate
Eli Lilly and Company
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERs
Brand：Inluriyo
Indications (approved)：Breast cancer, Metastatic breast cancer
Regional status
US
Approved
2025-09-25
EU
Approved
2026-01-09
China
Approved
2026-06-17
Japan
Approved
2025-12-22
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Imlunestrant Tosylate?
Approved indications include: Breast cancer, Metastatic breast cancer.
When does the Imlunestrant Tosylate patent expire?
No public expiry year is available for Imlunestrant Tosylate yet; this page updates once verified.
How do I get a quote for Imlunestrant Tosylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01